Overview

Study of 64Cu-FAPI-XT117 PET/CT in Patients With Malignant Solid Tumors

Status:
Completed
Trial end date:
2023-12-18
Target enrollment:
Participant gender:
Summary
This is the study of 64Cu-FAPI-XT117, which is an prospective, single-arm phase I clinical study.
Phase:
Phase 1
Details
Lead Sponsor:
The First Affiliated Hospital of Guangzhou Medical University
Collaborator:
Sinotau Pharmaceutical Group